Hillstream Biopharma (NASDAQ:CNTN) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Hillstream Biopharma (NASDAQ:CNTN) from a sell rating to a hold rating in a report issued on Saturday.

Separately, Weiss Ratings initiated coverage on shares of Hillstream Biopharma in a research report on Monday, March 9th. They issued a “sell (e+)” rating for the company. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Hillstream Biopharma Trading Down 3.5%

NASDAQ CNTN opened at $3.62 on Friday. The company has a fifty day simple moving average of $3.44. Hillstream Biopharma has a 12-month low of $1.08 and a 12-month high of $9.08. The firm has a market cap of $252.71 million, a P/E ratio of -1.84 and a beta of 1.44.

Hillstream Biopharma (NASDAQ:CNTN) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.23) earnings per share (EPS) for the quarter.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.